RESUMO
BACKGROUND: Elevated blood homocysteine is a risk factor for cardiovascular disease. A 5-micromol/L increase is associated with an approximately 70% increase in relative risk of cardiovascular disease in adults. For patients with established risk factors, this risk is likely even greater. OBJECTIVE: Effects of increased dietary folate and recommended intakes of vitamins B-12 and B-6 on serum total homocysteine (tHcy) were assessed in individuals at high risk of cardiovascular disease. DESIGN: This trial was conducted at 10 medical research centers in the United States and Canada and included 491 adults with hypertension, dyslipidemia, type 2 diabetes, or a combination thereof. Participants were randomly assigned to follow a prepared meal plan (PMP; n = 244) or a self-selected diet (SSD; n = 247) for 10 wk, which were matched for macronutrient content. The PMP was fortified to provide >/=100% of the recommended dietary allowances for 23 micronutrients, including folate. RESULTS: Mean folate intakes at 10 wk were 601 +/- 143 microgram/d with the PMP and 270 +/- 107 microgram/d with the SSD. With the PMP, serum tHcy concentrations fell from 10.8 +/- 5.8 to 9.3 +/- 4.9 micromol/L (P < 0.0001) between weeks 0 and 10 and the change was associated with increased intakes of folate, vitamin B-12, and vitamin B-6 and with increased serum and red blood cell folate and serum vitamin B-12 concentrations. tHcy concentrations did not change significantly with the SSD. CONCLUSIONS: The PMP resulted in increased intakes and serum concentrations of folate and vitamin B-12. These changes were associated with reduced serum tHcy concentrations in persons at high risk of cardiovascular disease.
Assuntos
Doenças Cardiovasculares/etiologia , Dieta , Ácido Fólico/uso terapêutico , Homocisteína/sangue , Piridoxina/uso terapêutico , Vitamina B 12/uso terapêutico , Adulto , Idoso , Análise de Variância , Diabetes Mellitus Tipo 2/complicações , Feminino , Ácido Fólico/administração & dosagem , Alimentos Fortificados , Humanos , Hiperlipidemias/complicações , Hipertensão/complicações , Masculino , Pessoa de Meia-Idade , Piridoxina/administração & dosagem , Fatores de Risco , Vitamina B 12/administração & dosagemRESUMO
Vitamin E is an antioxidant that has been demonstrated to improve insulin action. Glutathione, another natural antioxidant, may also be important in blood pressure and glucose homeostasis, consistent with the involvement of free radicals in both essential hypertension and diabetes mellitus. Our group has recently suggested that the effects of reduced glutathione on glucose metabolism may be mediated, at least in part, by intracellular magnesium levels (Mg([i])). Recent evidence suggests that vitamin E enhances glutathione levels and may play a protective role in magnesium deficiency-induced cardiac lesions. To directly investigate the effects of vitamin E supplementation on insulin sensitivity in hypertension, in relation to the effects on circulating levels of reduced (GSH) and oxidized (GSSG) glutathione and on Mg([i]), we performed a 4-week, double-blind, randomized study of vitamin E administration (600 mg/d) versus placebo in 24 hypertensive patients and measured whole-body glucose disposal (WBGD) by euglycemic glucose clamp, GSH/GSSG ratios, and Mg([i]) before and after intervention. The relationships among WBGD, GSH/GSSG, and Mg([i]) in both groups were evaluated. In hypertensive subjects, vitamin E administration significantly increased WBGD (25.56+/-0.61 to 31.75+/-0.53 micromol/kg of fat-free mass per minute; P<0.01), GSH/GSSG ratio (1.10+/-0.07 to 1.65+/-0.11; P<0.01), and Mg([i]) (1.71+/-0.042 to 1.99+/-0.049 mmol/L; P<0.01). In basal conditions, WBGD was significantly related to both GSH/GSSG ratios (r=0.58, P=0.047) and Mg([i]) (r=0.78, P=0.003). These data show a clinical link between vitamin E administration, cellular magnesium, GSH/GSSG ratio, and tissue glucose metabolism. Further studies are needed to explore the cellular mechanism(s) of this association.
Assuntos
Glucose/metabolismo , Glutationa/administração & dosagem , Hipertensão/tratamento farmacológico , Magnésio/metabolismo , Vitamina E/administração & dosagem , Método Duplo-Cego , Feminino , Teste de Tolerância a Glucose , Humanos , Hipertensão/metabolismo , Resistência à Insulina , Masculino , Pessoa de Meia-IdadeRESUMO
OBJECTIVE: We sought to establish and compare the distribution of intracellular and extracellular magnesium and pH in cord and maternal erythrocytes at the time of delivery. METHODS: We used 31P-nuclear magnetic resonance spectroscopy and a magnesium-specific ion-selective electrode apparatus to evaluate plasma and intracellular red cell content of free magnesium, pH, and ionized calcium in blood obtained from cord and corresponding maternal samples. RESULTS: Cord erythrocyte intracellular free magnesium content (110 +/- 4 mumol/L) and pH (7.02 +/- 0.01) were lower than corresponding maternal intracellular values (140 +/- 9 mumol/L, P < .05; and 7.20 +/- 0.02, P < .0005, respectively). The extracellular cord ionized magnesium concentration in plasma was closely related to the intracellular free magnesium concentration (r = 0.71, P < .005). Extracellular ionized magnesium and calcium were both greater in cord than in maternal samples (P < .05 and P < .0005, respectively). CONCLUSION: These data indicate a differential distribution of extracellular and intracellular magnesium and pH in cord versus maternal blood cells. We hypothesize that these deviations are physiological and may serve to maintain tissue oxygen delivery, while at the same time mediating the changes in vascular tone characteristic of birth.
Assuntos
Eritrócitos/metabolismo , Sangue Fetal , Magnésio/sangue , Adulto , Cálcio/sangue , Parto Obstétrico , Feminino , Idade Gestacional , Humanos , Concentração de Íons de Hidrogênio , Recém-Nascido , Espectroscopia de Ressonância Magnética/métodos , Troca Materno-Fetal , Oxigênio/sangue , Fósforo , GravidezRESUMO
To study the ionic basis of salt sensitivity in hypertension, 19F-, 13P-, and 23Na-nuclear magnetic resonance techniques were used to measure cytosolic free calcium (Cai), pH (pHi), free magnesium (Mgi), and sodium (Nai) in erythrocytes of essential hypertensive subjects (n = 19). Individuals were studied for 2 mo each on low- (UNaV < 50 meq/d) and high- (UNaV > 200 meq/d) salt diets, with the concomitant administration of nifedipine (10 mg t.i.d.) or placebo tablets for 1 mo of each diet. Salt loading elevated Cai and Nai while suppressing Mgi and pHi; these changes occurred predominantly in salt-sensitive subjects (n = 9). Nifedipine blunted the pressor response to salt loading > 50% (delta diastolic BP [high-low salt vs placebo] = 5 +/- 2 vs 14 +/- 2 mmHg, P < 0.05) and reversed salt-induced ionic changes, lowering Cai and elevating Mgi and pHi. Regardless of the definition of salt sensitivity, continuous relationships were observed between the pressure response to salt loading, the levels of Cai (r = 0.726, P < 0.001), Nai (r = 0.747, P < 0.001), and pHi (r = -0.754, P < 0.001), and the salt-induced change in Mgi (r = -0.757, P < 0.001). Altogether, these results emphasize the reciprocal and coordinate nature of intracellular ionic changes in response to dietary salt loading and calcium channel blockade in essential hypertension. They suggest that salt sensitivity is mediated by cellular calcium accumulation from the extracellular space, in association with magnesium depletion and acidification. Lastly, interpretation of intracellular ion measurements in the future will require concurrent assessment of dietary salt intake.
Assuntos
Pressão Sanguínea/efeitos dos fármacos , Hipertensão/fisiopatologia , Nifedipino/uso terapêutico , Sódio na Dieta/farmacologia , Análise de Variância , Cálcio/sangue , Eletrólitos/urina , Eritrócitos/efeitos dos fármacos , Eritrócitos/metabolismo , Feminino , Humanos , Concentração de Íons de Hidrogênio , Hipertensão/sangue , Hipertensão/terapia , Magnésio/sangue , Espectroscopia de Ressonância Magnética/métodos , Masculino , Pessoa de Meia-Idade , Nifedipino/farmacologia , Método Simples-Cego , Sódio/sangueRESUMO
Parathyroid hypertensive factor (PHF) in rats: PHF is an endogenous hypertensive substance which was originally associated with hypertension in spontaneously hypertensive rats (SHR). In this model, PHF was shown to act by increasing intracellular calcium levels in vascular smooth muscle and was linked with a characteristic pattern of abnormalities in overall calcium regulation. The action of PHF was blocked by calcium antagonists, suggesting that the effect of PHF was to increase extracellular calcium uptake. In SHR the parathyroid glands were shown to be the site of PHF secretion. This secretion was inhibited by an increase in dietary calcium. PHF was further shown to be unique to low-renin forms of hypertension, that is, those forms of hypertension characterized by abnormalities in calcium metabolism. PHF in humans: PHF was subsequently found in human low-renin salt-sensitive hypertension. As in SHR, calcium supplementation can lower PHF levels in humans. Similarly, there is circumstantial evidence for the parathyroid origin of PHF in humans. In human hypertensive patients, the presence of PHF has been shown to predict a favorable therapeutic response to calcium channel blockade. Recently, many of the abnormalities in calcium metabolism present in low-renin hypertension have also been described in other disease states. Notable among these diseases is non-insulin dependent diabetes mellitus. A survey of human non-insulin dependent diabetes mellitus has revealed that PHF was present in a disproportionate number of these patients independently of the blood pressure level. The significance of this latter finding needs to be explored, but PHF may prove to have relevance in diseases other than hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Fatores Biológicos/fisiologia , Hipertensão/etiologia , Animais , Cálcio/metabolismo , Bloqueadores dos Canais de Cálcio/farmacologia , Bloqueadores dos Canais de Cálcio/uso terapêutico , Diabetes Mellitus Tipo 2/metabolismo , Humanos , Hipertensão/tratamento farmacológico , Glândulas Paratireoides/fisiologia , RatosRESUMO
1. To determine whether abnormal renal calcium excretion is unique to primary genetic hypertension, blood pressure and 24 h urinary excretion of calcium, magnesium, sodium and creatinine were measured in deoxycorticosterone-saline and two-kidney, one-clip Goldblatt hypertensive rats and in their respective controls on low (0.2%) and high (1.8%) dietary calcium intakes. 2. Calcium supplementation lowered blood pressure (P < 0.05) in deoxycorticosterone-saline rats and in control saline-loaded rats, raised blood pressure in two-kidney, one clip rats, and had no effect in sham-operated control rats. 3. On both diets, calcium excretion was higher in hypertensive than in normotensive rats. The high calcium diet increased urinary calcium excretion in all rats, but the changes in urinary calcium excretion closely paralleled the diet-induced changes in blood pressure. Thus, urinary calcium excretion in deoxycorticosterone-saline animals, in whom calcium lowered blood pressure the most, rose the least (107%). Urinary calcium excretion rose the most in two-kidney, one-clip animals (1113%), whose blood pressure also rose the most. 4. Urinary magnesium excretion was also abnormal in hypertensive rats compared with normotensive rats, falling on the high compared with the low calcium diet in normotensive rats, but not in either hypertensive strain. Furthermore, urinary magnesium excretion was closely linked to urinary calcium excretion in saline-loaded control rats (r = 0.78; P = 0.008), but was dissociated from urinary calcium excretion in deoxycorticosterone-saline rats (r = 0.02; not significant).(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Cálcio/urina , Hipertensão Renovascular/fisiopatologia , Rim/fisiopatologia , Animais , Cálcio da Dieta/administração & dosagem , Hipertensão Renovascular/urina , Magnésio/urina , Masculino , Ratos , Ratos WistarRESUMO
Two parallel lines of research increasingly implicate calcium in the pathophysiology of hypertension. Studies at the molecular-cellular level reveal that, as part of a second messenger system, calcium plays a critical role in cellular responses that are of special relevance to blood pressure homeostasis. Investigations at the epidemiological and clinical levels have also increasingly involved calcium in hypertension, although the data produced are often contradictory, suggesting alternately that hypertension involves excess calcium and that the disorder is associated with a calcium deficiency. In our own research, which emphasizes both the biochemical and the clinical heterogeneity of the hypertensive process, we have found that divalent cation metabolism may be shifted in both directions away from average normotensive values among different types of hypertension. In addition, these calcium metabolic shifts appear to mediate the pressor effects of salt in both human and experimental forms of hypertension and may help identify individuals for whom different therapeutic regimens would be appropriate. We have developed a working cellular hypothesis in which all forms of hypertension are seen as calcium-dependent. One form is more critically dependent on extracellular calcium and is characterized by low plasma renin activity, dietary salt sensitivity, and therapeutic responsiveness to oral calcium supplementation and to calcium-channel blockade. At the opposite extreme, the intracellular calcium-dependent, angiotensin II-mediated form is characterized by high renin, lack of salt sensitivity, and preferential response to beta-blockade and converting-enzyme inhibition.
Assuntos
Cálcio/metabolismo , Hipertensão/fisiopatologia , Administração Oral , Cálcio/uso terapêutico , Bloqueadores dos Canais de Cálcio/uso terapêutico , Dieta , Espaço Extracelular/metabolismo , Humanos , Hipertensão/tratamento farmacológico , Membranas Intracelulares/metabolismo , Modelos Cardiovasculares , Cloreto de Sódio/farmacologiaRESUMO
Ionic, hormonal, and blood pressure responses to a single oral dose of the calcium channel blocker nifedipine were assessed in 25 essential hypertensive subjects. When grouped according to their renin-sodium profile, low renin subjects had a greater hypotensive response to nifedipine (change in diastolic blood pressure -20.0 +/- 1.4 vs -6.4 +/- 1.0%; p less than 0.005) than did high renin hypertensive subjects. The initial level of serum ionized calcium predicted the blood pressure response to nifedipine (r = 0.70, p less than 0.001), as did the initial plasma renin activity (r = 0.65, p less than 0.005). Nifedipine induced a transient rise in serum ionized calcium (from 2.22 +/- 0.02 to 2.28 +/- 0.02 mEq/L; p less than 0.01), while plasma renin activity was consistently elevated compared with initial values at 30 (p less than 0.01), 60 (p less than 0.01), and 120 (p less than 0.05) minutes after drug administration. By comparison, plasma aldosterone levels did not rise and even declined at 30 (p less than 0.01), 60 (p less than 0.05), and 120 (p less than 0.05) minutes after nifedipine. These results suggest that low renin hypertension is more critically dependent on extracellular calcium than are higher renin forms and demonstrate that levels of serum ionized calcium, plasma renin activity, or both may predict the sensitivity of blood pressure to calcium channel blockade. Lastly, calcium may play a pivotal role in vivo in coupling renin stimulation to adrenal aldosterone responses.
Assuntos
Aldosterona , Pressão Sanguínea/efeitos dos fármacos , Cálcio/metabolismo , Hipertensão/metabolismo , Nifedipino/uso terapêutico , Sistema Renina-Angiotensina , Humanos , Hipertensão/tratamento farmacológicoRESUMO
Calcium metabolism plays an important role in blood pressure homeostasis, although it remains unclear to what extent calcium contributes to or, alternatively, protects against clinical hypertension. To resolve this confusion, hypertensive subgroups were first defined by plasma renin activity, dietary salt sensitivity, sensitivity to calcium channel blockade, and calcium metabolic indices. Using these classification schemes, different patterns of calcium metabolism emerged, each predictive of divergent clinical responses. Patients with low plasma renin activity, low serum ionized calcium levels, and dietary salt sensitivity, such as black and elderly hypertensive patients, may preferentially benefit from calcium supplementation. It is postulated that calcium-regulating hormones and the renin-angiotensin-aldosterone system coordinately monitor dietary mineral intake, and transduce these environmental signals at the cellular level by altering cellular calcium uptake and disposition. Analysis of these hormonal systems is useful diagnostically in defining those patients who would most benefit from non-pharmacologic dietary forms of treatment.
Assuntos
Cálcio/metabolismo , Hipertensão/metabolismo , Adulto , Idoso , Animais , Pressão Sanguínea/efeitos dos fármacos , Cálcio/uso terapêutico , Bloqueadores dos Canais de Cálcio/uso terapêutico , Feminino , Humanos , Hipertensão/terapia , Modelos Biológicos , Ratos , Renina/sangue , Sistema Renina-Angiotensina/efeitos dos fármacos , Cloreto de Sódio/metabolismoRESUMO
Hypertensive disease is associated with various abnormalities of calcium metabolism although how these abnormalities relate to the elevated pressure remains unclear. Based on the use of renin-sodium profiling, we have defined heterogeneous deviations in circulating levels of ionized calcium and magnesium as well as of the calcium-regulating hormones parathyroid hormone, calcitonin, and 1,25-dihydroxyvitamin D (1,25D), which parallel similar deviations in plasma renin activity. Essential hypertensive subjects with a profile of low renin, lower ionized calcium, and elevated 1,25D respond best to the calcium channel blocker nifedipine, demonstrate an enhanced sensitivity to the blood pressure effects of dietary salt loading, and have significantly lower blood pressures in response to oral calcium supplementation. Hypertensive subjects with the opposite metabolic profile--higher renin activity, higher serum ionized calcium, and lower 1,25D levels--are relatively insensitive to the blood pressure effects of either dietary salt loading or nifedipine, and show no significant hypotensive response to calcium supplements. Altogether, these alterations of calcium ionic and hormonal metabolism suggest that the hormonal control of calcium metabolism is linked to renin system activity as well as to the pathophysiology of the hypertensive process.
Assuntos
Cálcio/metabolismo , Hipertensão/metabolismo , Renina/sangue , Calcitonina/sangue , Calcitriol/sangue , Cálcio/uso terapêutico , Bloqueadores dos Canais de Cálcio/farmacologia , Humanos , Hipertensão/tratamento farmacológico , Magnésio/sangue , Hormônio Paratireóideo/sangue , Sódio/administração & dosagemRESUMO
Alterations of calcium metabolism in hypertensive disease have been increasingly observed, although the specific manner in which these alterations contribute to the increased blood pressure remains unclear. We have studied calcium metabolism in essential hypertension and have adopted an approach based on analysis of renin system activity, which emphasizes the heterogeneity of human hypertensive disease. With this approach we have defined parallel deviations of plasma renin activity, circulating ionized calcium, and calcium-regulating hormones, which suggest a calcium deficiency in some hypertensives and, an excess of calcium in others. These deviations can be used to predict and may mediate the blood pressure sensitivity of hypertensives to dietary salt, and may also target those individuals most likely to benefit from oral calcium supplementation. Calcium itself has enhanced antihypertensive effects in low renin subjects, having lower ionized calcium and higher endogenous 1,25-dihydroxyvitamin D values, and in subjects on higher dietary salt intakes. Calcium may alter pressure, at least in part, by suppressing endogenous vitamin D metabolites and by stimulating calcitonin secretion. We hypothesize that calcium-regulating hormones participate in the physiology of the renin-angiotensin system and in the pathophysiology of human hypertension.
Assuntos
Cálcio da Dieta/uso terapêutico , Hipertensão/dietoterapia , Pressão Sanguínea/efeitos dos fármacos , Cálcio/metabolismo , Humanos , Hipertensão/fisiopatologia , Renina/sangue , Sódio/farmacologiaRESUMO
A role for calcium in human hypertensive disease has been suggested. However, the various, apparently contradictory, abnormalities of calcium metabolism observed in experimental and clinical hypertension do not allow for unambiguous description of the specific manner in which calcium contributes to the hypertensive process. We studied calcium metabolism in essential hypertension and used renin-sodium profiling, which reveals the biochemical heterogeneity of clinical hypertension. We observed renin-linked, heterogeneous deviations in circulating levels of the divalent cations, magnesium and ionized calcium, in addition to deviations in the calcium-regulating hormones, parathyroid hormone (PTH), calcitonin (CT), and 1,25 dihydroxyvitamin D (1,25 D). These renin-calcium metabolic deviations may both predict and contribute to the pathophysiology of salt-induced hypertension, the blood pressure effects of oral calcium supplementation, as well as the short and longer term effectiveness of calcium channel blockade. Altogether, these data suggest an intimate linkage between the hormonal control of calcium metabolism, the renin-angiotensin system and blood pressure regulation in human hypertension.
Assuntos
Bloqueadores dos Canais de Cálcio/uso terapêutico , Cálcio/fisiologia , Hipertensão/fisiopatologia , Cálcio/sangue , Cálcio/uso terapêutico , Hormônios/sangue , Humanos , Hipertensão/sangue , Hipertensão/tratamento farmacológico , Magnésio/sangue , Cloreto de Sódio/farmacologiaRESUMO
The renin-angiotensin-aldosterone system regulates blood pressure and volume homeostasis in addition to sodium and potassium metabolism, and may be linked to divalent cation metabolism as well as hypertensive disease. In essential hypertension, circulating serum magnesium and Ca++, and the calcium regulating hormones, parathyroid hormone, calcitonin and 1,25 dihydroxyvitamin (1,25D) are different in the various renin subgroups. Elevated blood pressure induced by such maneuvers as dietary salt loading is associated with exacerbations of these calcium metabolic deviations, and appears related to salt-induced changes in serum Ca++ or 1,25D levels. Short- or longer-term lowering of blood pressure with the calcium-channel blocker, nifedipine, or with calcium or magnesium supplementation is associated with a shift of renin system activity and calcium metabolic indexes back to average normotensive values in those subjects most susceptible to these hypotensive agents. These observations suggest that deviations in calcium metabolism in essential hypertension may be related to the pathophysiology of the hypertensive process. Further, renin system activity and calcium metabolic indexes such as serum Ca++ levels may help target specific subgroups of hypertensive populations most susceptible to various dietary or drug maneuvers, and thus may provide a basis to better understand and treat clinical hypertension.
Assuntos
Bloqueadores dos Canais de Cálcio/uso terapêutico , Cálcio/metabolismo , Hipertensão/tratamento farmacológico , Sistema Renina-Angiotensina , Antagonistas Adrenérgicos beta/uso terapêutico , Inibidores da Enzima Conversora de Angiotensina , Animais , Pressão Sanguínea , Calcitonina/metabolismo , Dieta Hipossódica , Di-Hidroxicolecalciferóis/metabolismo , Diuréticos/uso terapêutico , Humanos , Hipertensão/dietoterapia , Hipertensão/metabolismo , Magnésio/metabolismo , Hormônio Paratireóideo/metabolismo , Cloreto de Sódio/administração & dosagemRESUMO
Despite recent appreciation of a role for calcium in clinical hypertension, evidence at present is conflicting. Thus, certain studies suggest increased calcium availability may be associated with increased levels of blood pressure, while others suggest that a calcium deficiency may contribute to the pathogenesis of hypertensive disease. Our own group has thus far demonstrated deviations of circulating levels of ionized calcium and of magnesium in essential hypertension, linked with concurrent deviations in the activity of the renal pressor hormone, renin. Furthermore, calcium metabolic indices may predict and even determine dietary sodium sensitivity in hypertension, as well as the blood pressure responsiveness to antihypertensive drug therapy. Moreover, oral calcium supplementation may itself possess antihypertensive actions in specifically targeted renin subgroups of essential hypertensive subjects. Altogether, these results link calcium metabolism, renin system activity, and the pathogenesis of hypertensive disease. It may ultimately be calcium-regulating hormones, which determine cellular disposition of calcium, rather than circulating levels of calcium itself, that mediate the blood pressure and possibly even the renin deviations observed among differing hypertensive individuals.